Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by Wino115on Jan 18, 2021 9:59pm
311 Views
Post# 32323659

The 2025 Plan

The 2025 Plan

I'm not sure why they are afraid to discuss the financial implications of the future, with all the risk warnings we would know.  Here is an example from another investment I have, Plug Power.  Now I fully realize the huge difference between a more predictable industrial roll-out with fewer "binary" events, but that shouldn't stop them from discussing their strategic plan and putting wide bands around it.    

Plug Power put in place a 2024 plan with EBITDA and Sales targets and adjusts it as they go along telling you where they are.  Here's their investor presentation with the 3rd page being The 2024 Plan with their strategic financial targets. Smart investors know these are just targets, not guarantees and it shows what they are aiming for.   


[url=https://https://www.ir.plugpower.com/Home/default.aspx]plug Power IR[/url]

<< Previous
Bullboard Posts
Next >>